1 / 42

Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance

Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance. MENDEL: AMG 145 Monotherapy for Hypercholesterolemia. LAPLACE-TIMI 57: AMG 145 Combined With Statin for Hypercholesterolemia . GAUSS: AMG 145 in Statin Intolerance. Dosing and Administration. GLAGOV Trial .

tino
Download Presentation

Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance

  2. MENDEL: AMG 145 Monotherapy for Hypercholesterolemia

  3. LAPLACE-TIMI 57: AMG 145 Combined With Statin for Hypercholesterolemia

  4. GAUSS: AMG 145 in Statin Intolerance

  5. Dosing and Administration

  6. GLAGOV Trial

  7. JUPITER: Attaining an LDL-C Level < 50 mg/dL

  8. Phase 3 Trials

  9. Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance

  10. Genetic defects identified in FH

  11. ENHANCESimvastatin/Ezetimibe in FH

  12. OSLER Study: Long-term AMG 145 Therapy

  13. Safety of AMG 145

  14. How low is too low?

  15. Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance

  16. Genetics: PCSK9

  17. Loss-of-Function PCSK9 Mutation:Distribution of LDL-C Levels

  18. Diagnosis of FH

  19. Determinants of PCSK9 Efficacy

  20. Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance

  21. Timelines of Lipid-Lowering Agents

  22. Dallas Heart Study: Lipid Characteristics of African American Individuals With Nonsense Mutations in PCSK9

  23. Diagnosis and Treatment of FH

  24. Diagnosis and Treatment of FH

  25. Novel Approaches to Lipid Management: Modulating the PCSK9/LDL Receptor Balance

  26. ENHANCE: Heterozygous FH

  27. PCSK9 mAb vs Placebo on LDL-C Levels

  28. Statin Therapy: Muscular Adverse Effects

  29. Safety of Long-term AMG 145

  30. Lipid-Lowering Therapy Initiation

  31. Abbreviations

  32. Abbreviations (cont)

  33. References

  34. References (cont)

  35. References (cont)

  36. References (cont)

  37. References (cont)

More Related